Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%
04:54pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
01:03pm, Thursday, 17'th Feb 2022 GlobeNewswire Inc.
Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton Myasthenic Syndrome Community Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton
Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA
03:29pm, Monday, 14'th Feb 2022 Zacks Investment Research
Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.
Here's Why Momentum in Catalyst (CPRX) Should Keep going
01:50pm, Friday, 11'th Feb 2022 Zacks Investment Research
Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why Momentum in Catalyst (CPRX) Should Keep going
10:00am, Friday, 11'th Feb 2022
Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts See a 33% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
03:00pm, Thursday, 10'th Feb 2022 Zacks Investment Research
The consensus price target hints at a 33.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?
02:40pm, Thursday, 10'th Feb 2022 Zacks Investment Research
Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Wall Street Analysts See a 33% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
11:33am, Thursday, 10'th Feb 2022
The consensus price target hints at a 33.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse
10:45am, Tuesday, 08'th Feb 2022
Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.
Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity
03:27pm, Monday, 07'th Feb 2022 Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ: Full story available on Benzinga.com
Catalyst Pharmaceuticals expects Q4 revenues to rise 24% Y/Y; provides 2022 outlook
01:59pm, Monday, 07'th Feb 2022 Seeking Alpha
Catalyst Pharmaceuticals (CPRX) reported preliminary Q4 revenue estimates and 2022 outlook.Q4 2021 total revenues expected to increase ~24% Y/Y to ~$38M. Consensus Revenue Estimate for…
Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity
10:27am, Monday, 07'th Feb 2022
Catalyst Pharmaceuticals Inc CPRX anticipates Q4 FY21 sales of approximately $38 million (consensus of $38.09 million), up roughly 24% Y/Y. Get the Inside Access Traders Are Using to Profit More an
Catalyst gets court''s favorable judgement in FDA lawsuit over rival drug approval
02:51pm, Thursday, 03'rd Feb 2022 Seeking Alpha
Catalyst Pharmaceuticals <> said the District Court entered summary judgment in favor of the company in a lawsuit against the FDA.The District Court''s order implements the decision
Catalyst says appeals court issued mandate in its favor in FDA lawsuit
07:59pm, Friday, 28'th Jan 2022 Seeking Alpha
Catalyst Pharmaceuticals (CPRX) announced that the U.S
7 of the Top-Rated Pharmaceutical Stocks for Q1
02:27pm, Tuesday, 18'th Jan 2022
As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appea
